These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 33624623)
1. Systemic therapies for hepatocellular carcinoma: the present and the future. Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623 [TBL] [Abstract][Full Text] [Related]
2. Molecular therapies for HCC: Looking outside the box. Faivre S; Rimassa L; Finn RS J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496 [TBL] [Abstract][Full Text] [Related]
3. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Weinmann A; Galle PR Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209 [TBL] [Abstract][Full Text] [Related]
4. Review article: systemic treatment of hepatocellular carcinoma. Pinter M; Peck-Radosavljevic M Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640 [TBL] [Abstract][Full Text] [Related]
5. Current treatment options for hepatocellular carcinoma. Eugen K Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161 [TBL] [Abstract][Full Text] [Related]
6. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Cersosimo RJ Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092 [TBL] [Abstract][Full Text] [Related]
7. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331 [TBL] [Abstract][Full Text] [Related]
8. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Rimassa L; Wörns MA Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830 [TBL] [Abstract][Full Text] [Related]
11. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Tella SH; Kommalapati A; Mahipal A; Jin Z Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326 [TBL] [Abstract][Full Text] [Related]
12. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. Amaro CP; Tam VC Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211 [TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. Sun W; Cabrera R J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. Su D; Wu B; Shi L JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508 [TBL] [Abstract][Full Text] [Related]
15. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Bangaru S; Marrero JA; Singal AG Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082 [TBL] [Abstract][Full Text] [Related]
16. Systemic therapy of liver cancer. Demir T; Lee SS; Kaseb AO Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425 [TBL] [Abstract][Full Text] [Related]
17. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. Piñero F; Silva M; Iavarone M World J Gastroenterol; 2020 Apr; 26(16):1888-1900. PubMed ID: 32390700 [TBL] [Abstract][Full Text] [Related]
18. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Zhang CH; Li M; Lin YP; Gao Q Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapies for hepatocellular carcinoma. Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464 [TBL] [Abstract][Full Text] [Related]
20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Perera S; Kelly D; O'Kane GM Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]